AMCI Acquisition Corp II (AMCI) Peer Comparison
$3.89
$0.07
(1.83%)
As on 04-Sep-2026 13:21EDT
Market cap
$90 Mln
Revenue (TTM)
$6 Mln
P/E Ratio
--
P/B Ratio
9
Div. Yield
0 %
Edit
| AMCI Acquisition Corp II (AMCI) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
90 | 5,305 | 3,392 | 778 | 449 |
Revenue ($ Mln) |
6 | 440 | 2,883 | -- | 330 |
Net Profit ($ Mln) |
-24.79 | -1,435.01 | -118.30 | -134.20 | 100.20 |
Net Margin (%) |
-392.92 | -325.91 | -4.10 | -- | 30.33 |
RoE (%) |
-239.17 | -- | -- | -40.17 | 30.44 |
Price to Earnings |
-- | -- | -- | -- | 4.68 |
Price-To-Book |
9.03 | -- | 1.35 | -- | 1.31 |
Income Statement ($ Mln)
| AMCI Acquisition Corp II (AMCI) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
5.98 | 319.02 | 2,631.80 | -- | 335.44 |
|
Cost of Revenue
|
3.13 | 281.12 | 1,584.40 | -- | 46.04 |
|
Gross Profit
|
2.85 | 37.90 | 1,047.40 | -- | 289.40 |
|
Operating Expenses
|
3.36 | 262.45 | 899.40 | 0.17 | 146.67 |
|
Operating Profit (EBIT)
|
-0.51 | -224.55 | 148.00 | -0.17 | 142.73 |
|
Other Income
|
-- | -- | -- | -- | -- |
|
Profit before Tax
|
-24.81 | -288.03 | -159.30 | 0.38 | 142.73 |
|
Provision for Tax
|
0.00 | 0.58 | 16.20 | -- | 35.94 |
|
Profit after Tax (Net Income)
|
-24.82 | -288.62 | -198.30 | 0.38 | 106.84 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Consolidated Profit
|
-- | -- | -- | -- | -- |
Liabilities ($ Mln)
| AMCI Acquisition Corp II (AMCI) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
10.43 | -962.74 | -1,276.40 | 399.79 | 317.57 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Non-Current Liabilities
|
0.06 | 2,528.98 | 3,507.00 | 15.99 | 160.23 |
|
Current Liabilities
|
0.69 | 781.40 | 2,868.70 | 0.13 | 594.94 |
|
Total Liabilities
|
11.17 | 2,347.64 | 5,244.20 | 415.91 | 1,072.73 |
Assets ($ Mln)
| AMCI Acquisition Corp II (AMCI) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
0.12 | 1,452.11 | 3,924.70 | 414.85 | 349.32 |
|
Current Assets
|
11.06 | 895.54 | 1,319.50 | 1.06 | 723.41 |
|
Total Assets
|
11.17 | 2,347.64 | 5,244.20 | 415.91 | 1,072.73 |
|
Total Debt*
|
0.11 | 1,060.33 | 3,975.30 | -- | 152.49 |
|
Net Current Assets
|
-2.44 | 114.14 | -1,558.20 | 0.93 | -- |
Cashflow ($ Mln)
| AMCI Acquisition Corp II (AMCI) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-5.56 | 278.25 | 24.80 | -0.63 | 71.03 |
|
Cash Flow from Investing Activities
|
0.02 | -740.75 | -12.20 | -414.00 | 0.62 |
|
Cash from Financing Activities
|
12.18 | -63.10 | 114.30 | 415.37 | -1.08 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| AMCI Acquisition Corp II (AMCI) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-549.49 | -120.97 | -7.47 | -- | 24.90 |
|
ROE (%)
|
-613.18 | 32.38 | 17.08 | -- | 38.62 |
|
ROA (%)
|
-267.97 | -14.63 | -3.83 | -- | 9.34 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-414.95 | -90.47 | -7.53 | -- | 31.85 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| AMCI Acquisition Corp II (AMCI) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-0.41 | -0.38 | -0.18 | -- | 0.13 |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
-3,094.16 | 78.05 | -54.32 | -- | 41.10 |
|
EPS Growth (%)
|
-35.80 | 0.80 | -0.54 | -- | 0.40 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| AMCI Acquisition Corp II (AMCI) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-- | -19.80 | -13.35 | -- | 5.90 |
|
Price / Book Value
|
-- | -5.94 | -2.07 | -- | 1.99 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-- | -31.10 | 5.65 | -- | 2.71 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| AMCI Acquisition Corp II (AMCI) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.01 | -1.10 | -3.11 | -- | 0.48 |
|
Short term debt to equity ratio
|
0.01 | -0.03 | -1.08 | -- | 0.00 |
|
Current Ratio
|
16.10 | 1.15 | 0.46 | 8.13 | 1.22 |
|
Quick Ratio
|
14.50 | -- | -- | -- | -- |
|
Interest Coverage
|
-- | -87.90 | 0.39 | -- | 14.20 |
Operating Efficiency Ratios
| AMCI Acquisition Corp II (AMCI) | Core Scientific Inc (CORZ) | Lionheart III Corp (LION) | ChemoCentryx (CCXI) | Atlas Crest Investment Corp (ACIC) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
42.51 | 105.69 | 29.34 | -- | 61.95 |
|
Asset Turnover
|
0.65 | 0.16 | 0.51 | -- | 0.29 |
|
Receivable days
|
168.27 | 193.60 | 125.70 | -- | 281.90 |
|
Inventory Days
|
271.54 | -5.77 | -5.88 | -- | -1,881.69 |
|
Payable days
|
997.67 | 94.44 | 58.42 | -- | 1,383.94 |
|
Cash Conversion Cycle
|
-557.86 | -84.42 | 68.68 | -- | -1,771.50 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
